| 05/12 | Lipocine Says Nonalcoholic Steatohepatitis Treatment Well Tolerated in Open-Label Exten.. | MT |
| 05/12 | Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results | PR |
| 05/12 | Lipocine Inc. Announces Positive LPCN 1144 Nash Open Label Extension Study Results | CI |
| 05/09 | LIPOCINE : Q1 Earnings Snapshot | AQ |
| 05/09 | Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022 | PR |
| 05/09 | Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 04/25 | Lipocine Inc. Grants Antares Pharma an Exclusive License to Commercialize TLANDO in the.. | CI |
| 04/11 | LIPOCINE : ANNOUNCES BOARD of DIRECTOR APPOINTMENTS - Form 8-K | PU |
| 04/11 | LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS | PR |
| 04/11 | Lipocine Inc. Announces Board Appointments | CI |
| 03/30 | Lipocine announces its partner received fda approval of tlando | AQ |
| 03/29 | Lipocine's Partner Company Secures US FDA Approval for Testosterone Replacement Therapy | MT |
| 03/29 | LIPOCINE : ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™ - Form 8-K | PU |
| 03/29 | LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™ | PR |
| 03/29 | Lipocine Inc. Announces Its Partner Received FDA Approval of TLANDO™ | CI |
| 03/15 | Top Premarket Decliners | MT |
| 03/09 | Earnings Flash (LPCN) LIPOCINE Posts Q4 Revenue $16.1M | MT |
| 03/09 | LIPOCINE : Announces Financial Results for the Year Ended December 31, 2021 - Form 8-K | PU |
| 03/09 | Lipocine Announces Financial Results for the Year Ended December 31, 2021 | PR |
| 03/09 | Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
| 03/07 | LIPOCINE : Management Change/Compensation - Form 8-K/A | PU |
| 03/01 | LIPOCINE : Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH - Form 8-K | PU |
| 03/01 | Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH | PR |
| 03/01 | Lipocine Inc. Announces Regulatory Guidance on LPCN 1144 in Non-Cirrhotic Nash | CI |
| 02/04 | Lipocine announces its partner received fda acceptance of nda resubmission for tlando | AQ |
| 02/03 | LIPOCINE : ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO® -.. | PU |
| 02/03 | Lipocine announces its partner received fda acceptance of nda resubmission for tlando® | PR |
| 02/01 | Clene Names Morgan Brown as Finance Chief | MT |
| 01/28 | Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO | AQ |
| 01/27 | LIPOCINE : Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO® - Form.. | PU |
| 01/27 | Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO® | PR |
| 01/27 | Lipocine Inc. Announces Peer-Reviewed Publication of Positive Phase 3 Study Results for.. | CI |
| 01/21 | Lipocine Chief Financial Officer is Retiring | MT |
| 01/21 | Lipocine Inc. Announces CFO Changes | CI |
| 01/21 | Lipocine Inc. Announces Executive Changes | CI |
| 01/05 | Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference | PR |
| 2021 | LIPOCINE : ANNOUNCES patient dosed in its Phase 2 Study with LPCN 1148 for management of l.. | PU |
| 2021 | Lipocine Commences Dosing in Phase 2 Study of Liver Cirrhosis Drug | MT |
| 2021 | Lipocine announces patient dosed in its phase 2 study with lpcn 1148 for management of .. | PR |
| 2021 | Lipocine Inc. Announces Patient Dosed in its Phase 2 Study with LPCN 1148 for Managemen.. | CI |
| 2021 | LIPOCINE : Q3 Earnings Snapshot | AQ |
| 2021 | Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021 - F.. | PU |
| 2021 | Earnings Flash (LPCN) LIPOCINE Reports Q3 Revenue $55,000 | MT |
| 2021 | Lipocine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept.. | CI |
| 2021 | Lipocine's LPCN 1144 Wins US FDA Fast-Track Designation to Treat Non-Cirrhotic Non-Alco.. | MT |
| 2021 | Lipocine Gets FDA Fast-Track Designation for LPCN 1144 in Non-Cirrhotic NASH | DJ |
| 2021 | Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-.. | PU |
| 2021 | Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-.. | CI |
| 2021 | Lipocine Announces Multiple Poster Presentations At The American Association For The St.. | PU |
| 2021 | ANTARES PHARMA : Enters into exclusive license agreement with lipocine for tlando in u.s. | AQ |
| 2021 | LIPOCINE : And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO | AQ |
| 2021 | LIPOCINE : Signs Deal with Antares Pharma for Commercialization of Tlando in the US; Share.. | MT |
| 2021 | ANTARES PHARMA : Strikes Exclusive License Agreement For Oral Testosterone Replacement The.. | MT |
| 2021 | LIPOCINE : AND ANTARES PHARMA ENTER INTO U.S. Licensing Agreement to Commercialize TLANDO®.. | PU |
| 2021 | LIPOCINE : And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO® | PR |
| 2021 | TRANSCRIPT : Lipocine Inc. Presents at H.C. Wainwright 5th Annual NASH Investor Conference.. | CI |
| 2021 | LIPOCINE : to Present at The H.C. Wainwright 5th Annual NASH Investor Conference | PR |
| 2021 | LIPOCINE : Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO | AQ |
| 2021 | LIPOCINE : Resubmitted New-Drug Application for Tlando Affirmed by FDA | MT |
| 2021 | LIPOCINE : ANNOUNCES FDA AFFIRMATION of class 1 NDA RESUBMISSION FOR TLANDO® (Form 8-K) | PU |
| 2021 | LIPOCINE : Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO® | PR |
| 2021 | Lipocine Inc. Announces FDA Affirmation of Class 1 NDA Resubmission for Tlando® | CI |
| 2021 | LIPOCINE : to Present at The Cantor Fitzgerald Virtual Global Healthcare Conference | PR |
| 2021 | LIPOCINE INC.(NASDAQCM : LPCN) added to S&P Global BMI Index | CI |
| 2021 | LIPOCINE : to Present at The H.C. Wainwright 23rd Annual Global Investment Conference | PR |
| 2021 | LIPOCINE : HC Wainwright Adjusts Lipocine's Price Target to $3.50 From $2.50, Keeps Buy Ra.. | MT |
| 2021 | LIPOCINE : 1144 Presentation-LiFT Topline 36 Week Results | PU |
| 2021 | LIPOCINE : Both LPCN 1144 treatment arms met with statistical significance the pre-specifi.. | PU |
| 2021 | LIPOCINE : Says Liver Drug Candidate Met Primary Endpoint in Study | MT |
| 2021 | LIPOCINE : LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endp.. | PR |
| 2021 | Lipocine Inc. Announces Positive Topline 36-Week Results from Phase 2 Proof of Concept .. | CI |
| 2021 | LIPOCINE : Q2 Earnings Snapshot | AQ |
| 2021 | LIPOCINE : Announces Financial Results for the Second Quarter Ended June 30, 2021 | PR |
| 2021 | Lipocine Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 | CI |
| 2021 | AFTER HOURS WATCH LIST SCORECARD : Cidm, lpcn, rfil | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
